The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial loss in body size and enhance metabolic health, particularly c